Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leuprolide to Enhance Immune Reconstitution After Allogeneic BMT
NCT01338987Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2011
- Primary completion
- Dec 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of leuprolide in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), Chronic Myeloid Leukemia (CML), chronic myelomonocytic leukemia (CMML), sponsored by National Cancer Institute. Started Apr 2011; status: completed.
02
Drugs
leuprolide
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)Chronic Myeloid Leukemia (CML)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT01338987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01338987.